La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
BARCELONA, Spain I March 10, 2026 I La Merie Publishing announced the publication of the biologics market report for the calendar year 2025 covering individual sales data for more than 400 biologic products. The report “2025 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA” analyzes market volume and growth rates […]
MUC16: old target revisited with new technologies – a pipeline review STUTTGART, Germany I November 10, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting mucin 16 (MUC16): Pipeline of MUC16-Targeted Immunotherapy. This competitive intelligence report about MUC16-Targeted Immunotherapeutics […]
CDH6: clinical PoC of lead anti-CDH6 ADC boosts pipeline – a pipeline review STUTTGART, Germany I November 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting cadherin-6 (CDH6): Pipeline of CDH6-Targeted Immunotherapeutics. This competitive intelligence report about CDH6-Targeted […]
MUC1: an old target accessed with new technologies leading to first signs of clinical activity – a pipeline review STUTTGART, Germany I November 06, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting mucin 1 (MUC1): Pipeline of MUC1-Targeted […]
Claudin 18.2: a clinically validated target and plenty of improvement options with new drug modalities – a pipeline review STUTTGART, Germany I September 25, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting claudin 18.2 (CLDN18.2): Pipeline of Claudin […]
PD-L1 and 4-1BB (CD137): promising immuno-oncology therapy combination to overcome on-target-off-tumor toxicity – a pipeline review STUTTGART, Germany I September 24, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting CD47 or SIRPα: Pipeline of PD-L1 x 4-1BB (CD137) […]
CD47 and SIRPα: next generation inhibitors to show clinical benefit – a pipeline review STUTTGART, Germany I September 23, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting CD47 or SIRPα: Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy. This […]
Complement C5: a commercially successful and clinically effective treatment of C5 mediated diseases – a pipeline review STUTTGART, Germany I September 22, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting the complement C5 receptor or its ligand C5: […]
IL-6 and IL-6R: hot targets for underexploited indications – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active IL-6R antagonists and IL-6 inhibitors in R&D: Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors. This competitive intelligence report […]
CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD40 agonists and CD40/L antagonists in R&D: Pipeline of CD40 Agonists and […]
